As part of the National Institutes of Health (NIH) Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, NCATS supports and facilitates a variety of funding and collaboration opportunities designed to address the opioid crisis, including pain management.
- Current Funding Opportunities
- Translational Research Collaboration Opportunities
- Expired Funding Opportunities
Please note: Visit the NIH Guide for Grants and Contracts for the most current funding opportunities available from NCATS.
Current Funding Opportunities
(Daniel Soñé Photography)
- PAR-23-069: HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
- RFA-NS-23-007: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
- RFA-NS-23-006: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
Translational Research Collaboration Opportunities
How do I:
- Translate my animal-based research discovery into a human-based model for continued testing and development?
- Advance my research on a potential therapeutic from plated cells into more complex, human cell-based models?
- Modify my compound to make it a drug?
- Collect the necessary data on my compound to advance towards testing in humans? What steps are involved?
Are these questions that you are wrestling with on your therapeutic development project? NCATS welcomes your NIH HEAL Initiative-related proposals to advance promising compounds and human cell-based models through preclinical development as a team-based, research collaborations with NCATS’ intramural scientists in the Division of Preclinical Innovation.
- As research collaborators, you bring a wealth of background knowledge and a starting point for a particular translational project.
- NCATS scientists provide expertise and resources to transform those starting points into therapeutically useful tools, platforms, or investigational drugs.
- Approved projects result in formation of joint project teams that will work together to design and follow milestone-driven project plans to achieve pre-agreed to deliverables.
View a slide presentation on Developing Drugs and Testing Platforms for Pain, Addiction and Overdose in Collaboration with NCATS (PDF - 2.45MB).
To view a presentation on how to collaborate with NCATS scientists, please go to 5:34:00 in the following video: https://videocast.nih.gov/Summary.asp?Live=31408&bhcp=1.
Learn more about collaborating with NCATS scientists and how to submit a proposal.
Expired Funding Opportunities
- PAR-23-161: Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
- NOT-TR-23-021: Notice of Extension of the Due Date of PAR-23-161: "Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)"
- NOT-TR-23-014: Notice of Termination of PAR-22-058 Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18)
- NOT-TR-23-013: Notice of Termination of RFA-TR-22-013 Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
- NOT-TR-23-012: Notice of Termination of RFA-TR-22-011 HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21)
- RFA-TR-23-011: Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
- RFA-TR-23-010: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
- RFA-AT-23-002: HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
- NOT-OD-22-110: Notice of Special Interest (NOSI): Availability of Administrative Supplements for Helping to End Addiction Long-term (HEAL) Initiative awardees to make data Findable, Accessible, Interoperable, and Reusable (FAIR) through the HEAL Data Ecosystem
- PAR-22-058: Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
- NOT-TR-22-027: Notice of Correction to PAR-22-058 "Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)"
- PAR-22-057: Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
- NOT-TR-22-015: Notice of Early Termination of PAR-22-057 "Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)"
- RFA-NS-22-037: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required)
- RFA-NS-22-016: HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional)
- RFA-TR-22-012: Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed)
- NOT-TR-22-018: Notice of Availability of Application Information for RFA-TR-22-012 Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed)
- RFA-TR-22-011: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
- RFA-AT-22-003: HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required)
- NOT-NS-21-026: HEAL Initiative: Notice of Special Interest (NOSI): Limited Competition to Support Mentorship of Junior Investigators
- RFA-NS-21-015: HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)
- NOT-NS-20-049: Notice of Change in Expiration Date and Cancellation of Final Three Receipt Dates for RFA-NS-19-018 "HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)."
- NOT-NS-20-048: Notice of Change in Expiration Date and Cancellation of Final Three Receipt Dates for RFA-NS-19-017 "HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)."
- NOT-NS-20-047: Notice of Change in Expiration Date and Cancellation of Final Three Receipt Dates for RFA-NS-19-016 "HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)."
- NOT-NS-20-023: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-18-906 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
- NOT-NS-20-020: Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
- NOT-AR-20-016: HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions
- NOT-AR-20-012: HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions
- RFA-NS-20-011: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)
- RFA-NS-20-009: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
- NOT-EB-20-009: Notice of Change in Expiration Date of RFA-EB-18-003 "HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)"
- NOT-TR-20-008: Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome
- RFA-AT-20-004: HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trials Optional)
- RFA-NS-19-021: HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
- NOT-NS-19-028: Notice of Change to Key Dates for RFA-NS-19-021 "HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)"
- RFA-NS-19-018: HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)
- NOT-TR-19-018: HEAL Initiative: Announcement of Collaboration Opportunities for Developing Drugs and Human Cell-Based Testing Platforms for Pain, Addiction and Overdose
- NOT-TR-19-025: Notice of Change to HEAL Initiative: Announcement of Collaboration Opportunities for Developing Drugs and Human Cell-Based Testing Platforms for Pain, Addiction and Overdose
- RFA-NS-19-017: HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)
- RFA-NS-19-016: HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)
- NOT-TR-19-009: Notice of Correction to Revise Application Due Dates for NOT-TR-19-001 Notice of Availability of Administrative Supplements for Microphysiological Systems Developers: Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose
- RFA-TR-19-005: HEAL Initiative: Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 Clinical Trial Not Allowed)
- RFA-TR-19-003: HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
- NOT-TR-18-031: HEAL Initiative: Announcement of the NCATS ASPIRE Design Challenges to Develop Innovative and Catalytic Approaches Towards Solving the Opioid Crisis
- RFA-EB-18-003: HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)
The NIH HEAL Pain Management Effectiveness Research Network (NIH HEAL Pain Management ERN)
Using NCATS’ Clinical and Translational Science Awards Trial Innovation Network, the NIH HEAL Pain Management ERN will support studies to compare the effectiveness of existing pain treatments and novel approaches to prevent and manage pain while reducing the risk of addiction. The goal is to provide clinicians with information about the effectiveness of treatments or management strategies that reduce opioid use and pain associated with many types of diseases or conditions. Learn more about how the NIH HEAL Pain Management ERN will use the Trial Innovation Network for these studies.
